{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:59:57Z","timestamp":1791172797517,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["2023KJ032"],"award-info":[{"award-number":["2023KJ032"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014761","name":"Natural Science Foundation of Qingdao","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2025MS1208"],"award-info":[{"award-number":["ZR2025MS1208"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109904","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:53:49Z","timestamp":1776754429000},"page":"109904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis, and anti-inflammatory evaluation of novel N-(Benzol[d]oxazol-5-yl)sulfonamides as NLRP3 inflammasome inhibitors"],"prefix":"10.1016","volume":"177","author":[{"given":"Zhendi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.109904_bb0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41577-024-01075-9","article-title":"Inflammasome components as new therapeutic targets in inflammatory disease","volume":"25","author":"Coll","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109904_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109904_bb0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","article-title":"Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction","volume":"75","author":"Ma","year":"2023","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109904_bb0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41590-025-02230-7","article-title":"The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets","volume":"26","author":"Weber","year":"2025","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109904_bb0025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.tins.2023.07.009","article-title":"Inflammasome assembly in neurodegenerative diseases","volume":"46","author":"Singh","year":"2023","journal-title":"Trends Neurosci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109904_bb0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109904_bb0035","doi-asserted-by":"crossref","first-page":"14447","DOI":"10.1021\/acs.jmedchem.3c01370","article-title":"Recent progress and prospects of small molecules for NLRP3 inflammasome inhibition","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109904_bb0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109904_bb0045","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1021\/acs.jmedchem.4c02759","article-title":"Discovery of DFV890, a potent Sulfonimidamide-containing NLRP3 inflammasome inhibitor","volume":"68","author":"Shen","year":"2025","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109904_bb0050","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.1318","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of ZY-IL1 in three patients with Cryopyrin-associated periodic syndromes","volume":"13","author":"Hissaria","year":"2024","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109904_bb0055","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1021\/acs.jmedchem.2c01250","article-title":"Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): a potent and selective NLRP3 inhibitor","volume":"65","author":"McBride","year":"2022","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109904_bb0060","doi-asserted-by":"crossref","first-page":"14897","DOI":"10.1021\/acs.jmedchem.3c01398","article-title":"Discovery of clinical candidate NT-0796, a brain-penetrant and highly potent NLRP3 inflammasome inhibitor for neuroinflammatory disorders","volume":"66","author":"Harrison","year":"2023","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109904_bb0065","doi-asserted-by":"crossref","first-page":"14195","DOI":"10.1021\/acs.jmedchem.5c00781","article-title":"Discovery of AZD4144, a selective and potent NLRP3 inhibitor for the treatment of inflammatory diseases","volume":"68","author":"Johansson","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102282","article-title":"NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice","volume":"103","author":"Bultinck","year":"2026","journal-title":"Mol. Metab."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109904_bb0075","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/acs.jmedchem.2c00149","article-title":"Synthesis and pharmacological evaluation of new N-sulfonylureas as NLRP3 inflammasome inhibitors: identification of a hit compound to treat gout","volume":"65","author":"Narros-Fern\u00e1ndez","year":"2022","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2026.109904_bb0080","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1021\/acs.jmedchem.3c00894","article-title":"Novel sulfonylurea-based NLRP3 inflammasome inhibitor for efficient treatment of nonalcoholic steatohepatitis, endotoxic shock, and colitis","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109904_bb0085","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","article-title":"Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer","volume":"66","author":"Albanese","year":"2023","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2026.109904_bb0090","doi-asserted-by":"crossref","first-page":"20911","DOI":"10.1021\/acs.jmedchem.4c01376","article-title":"Novel macrocyclic NLRP3 inhibitors","volume":"67","author":"Mesch","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117783","article-title":"Discovery of novel non-sulfonylurea NLRP3 inflammasome inhibitors for the treatment of multiple inflammatory diseases","volume":"295","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109904_bb0100","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1021\/acs.jmedchem.4c02813","article-title":"Discovery of novel sulfonylurea NLRP3 inflammasome inhibitor for the treatment of multiple inflammatory diseases","volume":"68","author":"Liu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109904_bb0105","doi-asserted-by":"crossref","first-page":"17833","DOI":"10.1021\/acs.jmedchem.4c01857","article-title":"Deep-learning-driven discovery of SN3-1, a potent NLRP3 inhibitor with therapeutic potential for inflammatory diseases","volume":"67","author":"Shi","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109904_bb0110","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109904_bb0115","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109904_bb0120","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1021\/acs.jmedchem.9b01155","article-title":"Discovery of second-generation NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"62","author":"Jiang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114468","article-title":"Development of sulfonamide-based NLRP3 inhibitors: further modifications and optimization through structure-activity relationship studies","volume":"238","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2026.109904_bb0130","doi-asserted-by":"crossref","first-page":"16141","DOI":"10.1021\/acs.jmedchem.3c01511","article-title":"Discovery of novel 2,3-Dihydro-1H-indene-5-sulfonamide NLRP3 inflammasome inhibitors targeting colon as a potential therapy for colitis","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107263","article-title":"Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors","volume":"146","author":"Huang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117927","article-title":"Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors","volume":"113","author":"Kang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107562","article-title":"Characterization of a small molecule inhibitor of the NLRP3 inflammasome and its potential use for acute lung injury","volume":"150","author":"Xu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.109904_bb0150","doi-asserted-by":"crossref","first-page":"15711","DOI":"10.1021\/acs.jmedchem.4c01341","article-title":"Discovery of potent, specific, and orally available NLRP3 inflammasome inhibitors based on pyridazine scaffolds for the treatment of septic shock and peritonitis","volume":"67","author":"Fu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2026.109904_bb0155","doi-asserted-by":"crossref","first-page":"20780","DOI":"10.1021\/acs.jmedchem.4c02350","article-title":"Discovery of NP3-253, a potent brain penetrant inhibitor of the NLRP3 inflammasome","volume":"67","author":"Mackay","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109904_bb0160","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1021\/acs.jmedchem.4c03108","article-title":"Discovery of potent and brain-penetrant bicyclic NLRP3 inhibitors with peripheral and central in vivo activity","volume":"68","author":"Mammoliti","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117796","article-title":"Discovery and structure-activity relationship studies of 3-pyridazinesulfonyl derivatives as a new class of inhibitors against NLRP3 inflammasome-dependent pyroptosis","volume":"296","author":"Nan","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109904_bb0170","doi-asserted-by":"crossref","first-page":"23532","DOI":"10.1021\/acs.jmedchem.5c02412","article-title":"Discovery of NP3-742: a structurally diverse NLRP3 inhibitor identified through an unusual phenol replacement","volume":"68","author":"Velcicky","year":"2025","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109904_bb0175","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.jmedchem.3c02098","article-title":"Discovery of potent, orally bioavailable, tricyclic NLRP3 inhibitors","volume":"67","author":"Velcicky","year":"2024","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2026.109904_bb0180","doi-asserted-by":"crossref","first-page":"13428","DOI":"10.1021\/acs.jmedchem.3c00696","article-title":"Discovery of triazinone derivatives as novel, specific, and direct NLRP3 inflammasome inhibitors for the treatment of DSS-induced ulcerative colitis","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109904_bb0185","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109904_bb0190","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1021\/acs.jmedchem.4c00504","article-title":"Hit-to-Lead optimization of the natural product oridonin as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activity","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109904_bb0195","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1021\/acs.jmedchem.2c01967","article-title":"Scaffold hybrid of the natural product tanshinone i with piperidine for the discovery of a potent NLRP3 inflammasome inhibitor","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109904_bb0200","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/bph.16036","article-title":"Discovery of alantolactone as a naturally occurring NLRP3 inhibitor to alleviate NLRP3-driven inflammatory diseases in mice","volume":"180","author":"Li","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"43","key":"10.1016\/j.bioorg.2026.109904_bb0205","article-title":"Discovery, total synthesis, and anti-inflammatory evaluation of naturally occurring naphthopyrone-macrolide hybrids as potent NLRP3 inflammasome inhibitors","volume":"63","author":"Sun","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"26","key":"10.1016\/j.bioorg.2026.109904_bb0210","doi-asserted-by":"crossref","first-page":"18172","DOI":"10.1021\/jacs.4c06538","article-title":"Sorbremnoids a and b: NLRP3 inflammasome inhibitors discovered from spatially restricted crosstalk of biosynthetic pathways","volume":"146","author":"Zhang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109904_bb0215","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1021\/acs.jmedchem.4c00357","article-title":"Novel isoalantolactone-based derivatives as potent NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"67","author":"Zhao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109904_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscia.2024.100035","article-title":"Protective effect of lycorine hydrochloride against diabetic nephropathy in high-fat diet and streptozotocin-induced diabetic mice","volume":"2","author":"Fang","year":"2024","journal-title":"Pharm Sci Adv."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109904_bb0225","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1021\/acs.jmedchem.4c02648","article-title":"Peripheral evolution of tanshinone IIA and cryptotanshinone for discovery of a potent and specific NLRP3 inflammasome inhibitor","volume":"68","author":"Zhu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109904_bb0230","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1021\/acs.jmedchem.3c02407","article-title":"Discovery and development of NLRP3 inhibitors targeting the LRR domain to disrupt NLRP3-NEK7 interaction for the treatment of rheumatoid arthritis","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109904_bb0235","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1021\/acs.jmedchem.0c01924","article-title":"Development of novel tetrahydroquinoline inhibitors of NLRP3 inflammasome for potential treatment of DSS-induced mouse colitis","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109904_bb0240","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20242403","article-title":"Discovery of potent and selective inhibitors of human NLRP3 with a novel mechanism of action","volume":"222","author":"Wilhelmsen","year":"2025","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109904_bb0245","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109904_bb0250","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/cts.13576","article-title":"First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers","volume":"16","author":"Tang","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109904_bb0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12974-019-1471-y","article-title":"A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury","volume":"16","author":"Kuwar","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109904_bb0260","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12964-025-02239-3","article-title":"JC124 confers multimodal neuroprotection in epilepsy by suppressing NLRP3 inflammasome activation: evidence from animal and human neuronal models","volume":"23","author":"Zhang","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109904_bb0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s41061-024-00477-6","article-title":"The benzoxazole heterocycle: a comprehensive review of the most recent medicinal chemistry developments of antiproliferative, brain-penetrant, and anti-inflammatory agents","volume":"382","author":"Di Martino","year":"2024","journal-title":"Top Curr Chem (Cham)."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109904_bb0270","article-title":"Inflammasome: structure, biological functions, and therapeutic targets","volume":"4","author":"Dai","year":"2023","journal-title":"MedComm (2020)"},{"issue":"22","key":"10.1016\/j.bioorg.2026.109904_bb0275","doi-asserted-by":"crossref","first-page":"24260","DOI":"10.1021\/acs.jmedchem.5c02163","article-title":"Mechanistic characterization of a small molecule as a direct NLRP3 inhibitor via binding to the NACHT domain","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:01:08Z","timestamp":1783191668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":55,"alternative-id":["S0045206826004402"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109904","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and anti-inflammatory evaluation of novel N-(Benzol[d]oxazol-5-yl)sulfonamides as NLRP3 inflammasome inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109904"}}